血小板膜蛋白CD63、CD62P表达与高血压分级、危险度分层的关系及药物干预作用

The changes of platelet CD63、CD62P levels and effects of angiotensinⅡ type 1 receptor antagonism on them in essential hypertension

目的 :探讨血小板颗粒膜蛋白 (CD6 3)、α-溶酶体膜蛋白 (CD6 2 P)与高血压分级、危险度分层的相关性及氯沙坦降压治疗对两者的影响。方法 :应用流式细胞术 (FCM)检测 86例高血压病患者血小板膜活性蛋白标志CD6 2 P、 CD6 3含量 ,同时观察氯沙坦降压治疗后上述指标的变化。结果 :高血压病患者的 CD6 3、 CD6 2 P均明显高于正常对照组 (P<0 .0 5或 P<0 .0 1) ,随着高血压病患者血压分级水平及危险度分层递增 ,CD6 3、CD6 2 P含量逐级增加 ,差异显著 (P<0 .0 5～ <0 .0 1)。氯沙坦治疗高血压病患者 8周后 ,CD6 3、 CD6 2 P的水平均明显下降 (P<0 .0 5～ <0 .0 1)。结论 :血小板 CD6 3、CD6 2 P水平与高血压病患者病情严重程度呈一定相关性。氯沙坦可降低血小板活化功能。

Objective:To explore the correlation among platelet activation factor CD63?CD62P and the stage?stratification of risk in essential hypertension(EH)and study an effect of angiotensin Ⅱ type 1 receptor antagonism(losartan) on them.Methods:CD63?CD62P were detected by flow cytometry in 86 patients with hypertension. Meanwhile, observed the change of above\|mentioned marker after losartan therapy.Results:CD63?CD62P concentration in EH were significantly higher than those of the normal subjects(P<005 or P<001);There were positive correlation among CD63?CD62P and hypertension stage?stratification of risk; platelet CD63?CD62P concentration decreased after 8 weeks losartan therapy(P<005 ~<001).Conclusion:There were positive correlation among CD63?CD62P and the hypertension stage?stratification of risk,CD63?CD62P may predict prognosis of EH.Losartan can decrease blood pressure and ameliorate the abnormality of platelet activation at same time.